Text Size

Patient-Reported Outcomes in the Treatment of Schizophrenia

This study has been completed.
Sponsor:
Information provided by:
Solvay Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00230828
First received: September 12, 2005
Last updated: September 6, 2007
Last verified: September 2007
History of Changes
  Purpose

Patient-reported health economic outcomes for patients enrolled in S1543003 and S1543004 protocols


Condition Intervention Phase
Schizophrenia
 Drug: bifeprunox
 Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Patient-Reported Outcomes With Bifeprunox or Olanzapine in the Treatment of Schizophrenia. A Pharmacoeconomic Study Carried Out in Connection With the S1543003 And S1543004 Clinical Trials

Resource links provided by NLM:

MedlinePlus related topics: Schizophrenia
U.S. FDA Resources

Further study details as provided by Solvay Pharmaceuticals:

Study Start Date: May 2005
  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participate in S1543003 and S1543004 in the U.S. sites

Exclusion Criteria:

  • Participate in S1543003 and S1543004 other than U.S. sites
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00230828

Sponsors and Collaborators
Solvay Pharmaceuticals
Investigators
Study Director: Global Clinical Director Solvay Solvay Pharmaceuticals
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00230828     History of Changes
Other Study ID Numbers: S154.3.005
Study First Received: September 12, 2005
Last Updated: September 6, 2007
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia and Disorders with Psychotic Features
Mental Disorders

ClinicalTrials.gov processed this record on May 22, 2013